Positive effects of acarbose in the diabetic rat are not altered by feeding schedule

Physiology and Behavior

Volumn 63, Issue 5, 1998, Pages 867-874

  Wright, Bruce E ^a   Vasselli, Joseph R ^b   Katovich, Michael J ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Acarbose Diabetes; Body weight; Glycated hemoglobin; Hyperglycemia; Meal feeding

Indexed keywords

ACARBOSE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN;

ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; FEEDING; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERPHAGIA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

EID: 18244417690     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-9384(98)00013-4     Document Type: Article

References (28)

1. Balfour J. A., McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs. 46:1993;1025-1054.
2. Cameron-Smith D., Collier G. R., O'Dea K. Reduction in the hyperglycemia by mild food restriction in streptozotocin induced diabetic rats improves insulin sensitivity. Norm. Metab. Res. 26:1994;316-321.
3. Cohen M. P., Klepser H., Wu V.-Y. Effect of alpha-glucosidase inhibition on the non-enzymatic glycation of glomerular basement membrane. Gen. Pharmacol. 22:1991;515-519.
4. Curi R., Hell N. S. Metabolic changes of twenty weeks food restriction schedule in rats. Physiol. Behav. 36:1986;239-243.
5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Eng. J. Med. 329:1993;977-986.
6. Glendinning J. I., Smith J. C. Consistency of meal patterns in laboratory rats. Physiol. Behav. 56:1994;7-16.
7. Gray R. S., Olefsky J. M. Effect of a glucosidase inhibitor on the metabolic response of diabetic rats to a high carbohydrate diet, consisting of starch and sucrose, or glucose. Metabolism. 31:1982;88-92.
8. Hillebrand I., Boehme K., Frank G., Fink H., Berchthold P. The effects of the α- glucosidase inhibitor BAY G 5421 (acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man. Res. Exp. Med. 175:1997;81-86.
9. Hoffmann J., Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. Diabetes Care. 17:1994;561-566.
10. Hotta N., Kakuta H., Sano T., Masumae H., Yamada H., Kitazawa S., Sakamoto N. Long term effect of acarbose on glycemic control in non-insulin-dependent diabetes mellitus: A placebo-controlled double-blind study. Diabet. Med. 10:1993;134-138.
11. Jenny A., Proietto J., O'Dea K., Nankervis A., Traianedes K., Oembden H. Low dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity. Diabetes Care. 16:1993;499-502.
12. Katovich, M. J. J.; Meldrum, M. J. Effects of insulin and acarbose alone and in combination in the female streptozotocin-induced diabetic rat. J. Pharm. Sci. 82:1209-11993.213; 1993.
13. Katovich M. J., Meldrum M. J., Vasselli J. R. Beneficial effects of dietary acarbose in the streptozotocin-induced diabetic rat. Metabolism. 40:1991;1275-1282.
14. Lebowitz H. E. Oral antidiabetic agents: The emergence of α-glucosidase inhibitors. Drugs. 44:1992;21-28.
15. Lee S. M. The effect of chronic alpha-glycosidase inhibition on diabetic nephropathy in the db/db mouse. Diabetes. 31:1982;249-254.
16. Leonhardt W., Hanefeld M., Fisher S., Schulze J. Efficacy of 181 -glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia. Eur. J. Clin. Invest. 24:(Suppl. 3):1994;45-49.
17. Lyons P. A., Gould S., Wise P. H., Palmer T. N. Activation of erythrocyte aldose reductase in man in response to a glucose challenge. Diabet. Res. Clin. Prac. 14:1991;9-14.
18. Madar Z. The effect of acarbose and miglitol (BAY M 1099) on postprandial glucose levels following ingestion of various sources of starch by nondiabetic and streptozotocin-induced diabetic rats. J. Nutr. 119:1989;2023-2029.
19. Madar Z., Omunsky Z. Inhibition of intestinal α-glucosidase activity and postprandial hyperglycemia by α-glucosidase inhibitors in fa/fa rats. Nutr. Res. 11:1991;1035-1046.
20. Marena S., Tagliaferro V., Cavallero G., Parani A., Montegrosso G., Bianchi W., Zaccarini P., Parango G. Double-blind crossover study of acarbose in type 1 diabetic patients. Diabet. Med. 8:1991;674-678.
21. Peterson R. G. 181 -Glucosidase inhibitors in diabetes: Lessons from animal studies. Eur. J. Clin. Invest. 24:1994;11-18.
22. Schmidt D. D., Frommer W., Junge B., Mueller L., Puls W., Truscheit E. Alpha-glucosidase inhibitors. New complex oligosaccharide of microbial origin. Naturwissenschaften. 64:1977;s535.
23. Thomas D. W., Scharrer E., Mayer J. Effects of alloxan-induced diabetes on the feeding patterns of rats. Physiol. Behav. 17:1976;345-349.
24. Toeller M. 181 -Glucosidase inhibitors in diabetes: Efficacy in NIDDM subjects. Eur. J. Clin. Invest. 24:(Suppl. 3):1994;31-35.
25. Tulp O. L., Haugaard N., Hess M. E. Effects of acarbose on glycemia, cholesterolemia, and cardiac function in non-insulin dependent diabetic corpulent rats. Diabet. Res. Clin. Pract. 5:1988;S620.
26. Vasselli J. R., Haraczkiewicz E., Maggio C. A., Greenwood M. R. C. Effects of a glucosidase inhibitor (acarbose, BAY G 5421) on the development of obesity and food motivated behavior in Zucker (fa/fa) rats. Pharm. Biochem. Behav. 19:1983;85-95.
27. Vasselli J. R., Haraczkiewicz E., Pi-Sunyer F. X. Effects of acarbose (BAY G 5421) on body weight, insulin, and glucose and sucrose tolerance in sucrose-consuming rats. Nutr. Behav. 1:1982;21-32.
28. Vedula U., Schnitzer-Polokoff R., Tulp O. L. The effect of acarbose on the food intake, weight gain, and adiposity of LA/N-cp rats. Comp. Biochem. Physiol. 100:1991;477-482.